{
    "nct_id": "NCT05899608",
    "official_title": "A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)",
    "inclusion_criteria": "* Age ≥ 18 years old at the time of enrollment\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* Expected life expectancy ≥ 3 months\n* Metastatic (Stage IV) NSCLC\n* Histologically or cytologically confirmed squamous or non-squamous NSCLC\n* Recorded measurement of the Tumor Proportion Score (TPS) for PD-L1 expression, irrespective of the PD-L1 expression, prior to randomization\n* At least one measurable noncerebral lesion according to RECIST 1.1\n* No prior systemic treatment for metastatic NSCLC\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Histologic or cytopathologic evidence of the presence of small cell lung carcinoma\n* Known actionable genomic alterations (EGFR, ALK, ROS1, and BRAF V600E) or genes for which first-line approved therapies are available.\n\n  * For non-squamous histology patients, actionable driver mutation testing results are required before randomization.\n* Has received any prior therapy for NSCLC in the metastatic setting\n* Tumor invasion, encasement of organs (e.g. heart, trachea, esophagus, central bronchi), or major blood vessels (e.g aorta, central veins), if poses a significant increased risk of bleeding.",
    "miscellaneous_criteria": ""
}